Latest news
Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies
Amsterdam, The Netherlands , July 22, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a...
VarmX to Present New Data on Lead Compound, VMX-C001,
at the ISTH 2021 Virtual Congress
Leiden, The Netherlands, 19 July 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new preclinical data on VMX-C001 has been selected to be presented during an oral...
Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer
Leiden, The Netherlands, June 30, 2021 – Azafaros B.V. today announced that Stefano Portolano, M.D., has joined Azafaros as Chief Executive Officer (CEO) and has concurrently been appointed to the Board of Directors of the company. Dr. Portolano is an experienced...
Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline
AMSTERDAM, NETHERLANDS – June 29, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today...
Next events
21-25 June – BioTrinity 2021
BioTrinity gives an opportunity to share updates on the latest achievments in R&D across all therapy and technology areas. BGV will be attending BioTrinity 2021 which features a packed LIVE agenda of Panels, Industry Insights, Keynotes, BioLaunchPad Presentations...
01 July, 2021 – BGV Partner Daniela Couto at Johnson & Johnson Innovation webinar
BGV Partner Daniela Couto will participate in the Johnson & Johnson Innovation webinar "Investor Perspective: How Can Partnering with Pharma Impact Startup Success?" A panel of investors will share their views on collaborating and partnering with pharma companies....
Latest investments
